Company Filing History:
6 out of 195 
4 out of 25 
Years Active: 2005-2016
Title: Innovations of Robert Ronald Kane
Introduction
Robert Ronald Kane is a notable inventor based in Waco, Texas, recognized for his contributions to the field of vascular targeting agents. With a total of six patents to his name, Kane has made significant strides in developing novel compounds that have the potential to revolutionize cancer treatment.
Latest Patents
Kane's latest patents include functionalized stilbene derivatives that serve as improved vascular targeting agents. These novel stilbenoid compounds and their prodrug forms are designed to be potent agents useful for treating solid tumor cancers and other diseases associated with unwanted neovascularization. The compounds are tubulin-binding stilbenoid analogs that are structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms of these compounds are particularly effective as vascular targeting agents (VTAs) for treating solid tumor cancers and diseases related to retinal neovascularization.
Career Highlights
Throughout his career, Kane has worked with esteemed institutions such as Baylor University and Oxigene, Inc. His work has focused on innovative solutions in the medical field, particularly in oncology.
Collaborations
Kane has collaborated with notable individuals in his field, including David J. Chaplin and Charles Manly Garner III. These collaborations have contributed to the advancement of his research and the development of his patented technologies.
Conclusion
Robert Ronald Kane's innovative work in developing vascular targeting agents showcases his commitment to improving cancer treatment. His contributions through his patents reflect a significant impact on medical research and therapeutic applications.